Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes
Phase of Trial: Phase I/II
Latest Information Update: 26 Oct 2018
Price : $35 *
At a glance
- Drugs Aldesleukin (Primary)
- Indications Acute coronary syndromes; Ischaemic heart disorders; Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms LILACS
- 31 Aug 2018 Biomarkers information updated
- 07 Jun 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 07 Jun 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.